Patents by Inventor Veronica Lifshitz

Veronica Lifshitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9757448
    Abstract: Methods for treating and reducing risk of cerebral amyloid angiopathy (CAA) using nasal vaccination with a proteosome adjuvant.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: September 12, 2017
    Assignees: The Brigham and Women's Hospital, Inc., Ramot At Tel Aviv University Ltd.
    Inventors: Howard Weiner, Dan Frenkel, Veronica Lifshitz
  • Patent number: 8691760
    Abstract: Use of an isolated peptide comprising an amino acid sequence being no more than 25 amino acids in length, the amino acid sequence comprising at least one aspartate or a homolog thereof, the peptide having an Insulin-Degrading Enzyme (IDE) inhibitory activity, for the manufacture of a medicament identified for treating a disease selected from the group consisting of diabetes, obesity, hyperglycemia, retinal damage, renal failure, nerve damage, microvascular damage and varicella-zoster virus (VZV) infection is disclosed.
    Type: Grant
    Filed: February 2, 2010
    Date of Patent: April 8, 2014
    Assignee: Ramot at Tel-Aviv University
    Inventors: Dan Frenkel, Adi Kopelevich, Veronica Lifshitz, Tali Benromano, Nofit Borenstein
  • Publication number: 20130183245
    Abstract: Methods for treating and reducing risk of cerebral amyloid angiopathy (CAA) using nasal vaccination with a proteosome adjuvant.
    Type: Application
    Filed: February 24, 2011
    Publication date: July 18, 2013
    Applicants: TEL AVIV UNIVERSITY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Howard Weiner, Dan Frenkel, Veronica Lifshitz
  • Publication number: 20120028894
    Abstract: Use of an isolated peptide comprising an amino acid sequence being no more than 25 amino acids in length, the amino acid sequence comprising at least one aspartate or a homolog thereof, the peptide having an Insulin-Degrading Enzyme (IDE) inhibitory activity, for the manufacture of a medicament identified for treating a disease selected from the group consisting of diabetes, obesity, hyperglycemia, retinal damage, renal failure, nerve damage, microvascular damage and varicella-zoster virus (VZV) infection is disclosed.
    Type: Application
    Filed: February 2, 2010
    Publication date: February 2, 2012
    Applicant: Ramot at Tel-Aviv University Ltd.
    Inventors: Dan Frenkel, Adi Kopelevich, Veronica Lifshitz, Tali Benromano, Nofit Borenstein